Skip to main content

Branded

  • FDA approves Perrigo’s hydrocodone bitartrate and homatropine methylbromide

    WASHINGTON — The U.S. Food and Drug Administration approved Perrigo’s hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL.

    Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL is indicated for the symptomatic relief of cough in adults and children 6 years of age and older. Annual sales for the 12 months ending January 2017 were approximately $16 million, according to Perrigo. 

  • Health care leaders gather in Washington

    WASHINGTON — Leaders across the health care continuum on Thursday gathered in Washington, D.C. to offer perspectives on efforts currently underway to move the healthcare system toward one that rewards innovation, delivers better quality and puts the patient at the center of the value equation. The meeting was convened by The Value Collaborative, an initiative of America’s biopharmaceutical companies, in partnership with Morning Consult.

  • Albertsons trains pharmacists to dispense prescription-free Naloxone spray in 13 states

    BOISE, Idaho — Albertsons on Thursday announced that it had trained 3,000 of its pharmacists under its various banners to administer Adapt Pharma’s Narcan Nasal Spray and counsel patient on how to use the opioid overdose reversal drug. 
     

  • FDA expands indication for Boehringer Ingelheim’s Spiriva Respimat

    SILVER SPRING, Md. — The Food and Drug Administration has approved an expanded indication for Boehringer Ingelheim Pharmaceuticals’ Spiriva Respimat (tiotropium bromide), the company announced Thursday. 
     
    The asthma maintenance treatment is now indicated for children ages 6 years and older. It had previously been approved as an asthma treatment for adults and adolescents. 
     

  • FDA approves Valeant’s Siliq for plaque psoriasis

    WASHINGTON — The U.S. Food and Drug Administration approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.

    Siliq is administered as an injection. It is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies. 

  • FDA approves Emflaza for Duchenne muscular dystrophy

    NORTHBROOK, Ill. — The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.

    Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system. It is marketed by Northbrook-based Marathon Pharmaceuticals.

  • Tom Price confirmed as HHS Secretary

    WASHINGTON — Rep. Tom Price, R-Ga., has been confirmed by the U.S. Senate to be America’s 23rd Secretary of the U.S. Department of Health and Human Services.

  • New study finds Tamiflu 'cost-effective' in most pandemic scenarios

    HOBOKEN, N.J. — A new study released Wednesday indicates that Genentech's antiviral drug Tamiflu (oseltamivir) can reduce influenza infections and prevent deaths in a cost-saving manner under most pandemic scenarios.

X
This ad will auto-close in 10 seconds